Breaking News

Catalent, Exelixis Extend Cometriq Partnership

December 7, 2012

Will serve as exclusive commercial supplier for U.S. market

Catalent has entered into an agreement with Exelixis to supply CometriqT (Cabozantinib) for the U.S. market. CometriqT has been approved by the FDA for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
 
Under an existing five-year partnership, Catalent has provided analytical, clinical trial supply and manufacturing support for Cometriq and will continue to be the exclusive commercial drug supply partner for the 20 mg and 80 mg capsule dose packs in the U.S. All capsule manufacturing and packaging operations will take place at Catalent’s 450,000-sq.-ft. facility in Kansas City, MO.
 
“Catalent supports pharmaceutical companies, small and large, to help them accelerate their drug development and bring new treatments to improve patient’s lives,” said Scott Houlton, president of Development and Clinical Services at Catalent. “We have worked closely with Exelixis over the past several years on COMETRIQ and are delighted to have reached this key milestone.”
 
“We have been pleased to partner with Catalent for the past five years. Catalent has provided high quality service for analytical testing, manufacturing process development and validation.  This partnership has truly helped advance this important product for cancer patients,” said JoAnn Wilson, vice president, Chemical, Manufacturing and Control at Exelixis, Inc.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016